Cure pharmaceutical launches psychedelic oral film program targeting the treatment of mental health disorders

Oxnard, calif.--(business wire)--cure pharmaceutical holding corp. (“cure” or the “company”) (otc: curr), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, lsd, and mdma for the treatment of various mental health disorders. utilizing cure's patented oral film platform curefilm® for precision dosing, the company intends to optimize the absorption an
CURR Ratings Summary
CURR Quant Ranking